

**Company announcement**  
No. 06/2020

**Orphazyme A/S**  
Ole Maaløes Vej 3  
DK-2200 Copenhagen N

www.orphazyme.com  
Company Registration No. 32266355

## **Capital increase of 20,650 shares (equivalent to approximately 0.10% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB**

**Copenhagen, Denmark, January 31, 2020** – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today decided on a capital increase as a result of a directed issue of bonus shares to Kansas Life Sciences Development Company, Inc. (“KLSDC”) and UCL Business Ltd. (“UCLB”). The capital increase was decided pursuant to the Board of Directors’ authorization laid down in Article 3.6 of the Articles of Association.

According to the license agreement entered into on October 31, 2017 between among others Orphazyme A/S, KLSDC, and UCLB, Orphazyme A/S shall, following the end of each calendar year, issue or otherwise deliver to KLSDC and UCLB a total number of shares equal to the aggregate amount of cash funding that KLSDC and UCLB have reported to have spent under the grant from the US Food and Drug Administration received with respect to Orphazyme A/S’ on-going phase 2/3 clinical trial on arimoclomol for the treatment of sIBM. On the basis of a financial report of expenditures provided by KLSDC and UCLB, Orphazyme A/S will issue 20,650 new shares each with a nominal value of DKK 1, equal to approximately 0.10% of its total share capital, in favor of KLSDC and UCLB. Accordingly, Orphazyme A/S’ share capital will be increased by nominally DKK 20,650 by way of an issue of bonus shares at par value by transfer of DKK 20,650 from Orphazyme’s distributable reserves. The number of shares to be delivered to KLSDC and UCLB has been calculated based on the average closing price of Orphazyme’s shares on Nasdaq Copenhagen during a 30-day period preceding the date of issuance.

The new shares are negotiable instruments and will in every respect carry the same rights as the existing shares from the time of registration of the capital increase with the Danish Business Authority (which is expected to occur today). The new shares are expected to be admitted to trading and official listing on Nasdaq Copenhagen on or around February 3, 2020.

Following the share capital increase, the total nominal share capital will be DKK 20,005,449, divided into 20,005,449 shares each with a nominal value of DKK 1. Each share carries one vote at Orphazyme’s general meetings and accordingly the total number of voting rights in Orphazyme will be 20,005,449. Updated Articles of Association can be found at [www.orphazyme.com](http://www.orphazyme.com).

**For additional information, please contact**

### **Orphazyme A/S**

Anders Vadsholt, CFO +45 28 98 90 55

### **About Orphazyme A/S**

Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit [www.orphazyme.com](http://www.orphazyme.com).

### **Forward-looking statement**

This company announcement may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.